John Libbey Eurotext

Virologie

MENU

Passive immunotherapy in Sars-Cov2 infections Volume 25, issue 6, Novembre-Décembre 2021

Figures

  • Figure 1
  • Figure 2

Tables

Authors
1 Institut Lavoisier de Versailles, UMR CNRS 8180, Université Paris-Saclay, Université de Versailles St-Quentin-en-Yvelines 78035 Versailles cedex, France
2 LRN EA4682 URCA Reims, Pôle Santé, 5 rue Cognacq-Jay, 51100 Reims, France
* Correspondance

This article presents the current situation by November 2021 of the prophylactic or therapeutical use of polyclonal or monoclonal antibodies in Covid-19, either as immuno-modulators, or directly directed towards the virus.